TOKYO, Apr 24 (Pulse News Wire) – Nano Holdings,inc. (4571.T) announced today that its strategic subsidiary, NANO MRNA, has decided to acquire Luna RD through a third-party allotment capital increase.
This move aims to strengthen NANO MRNA's technology base by securing key patents held by Luna RD, which specializes in next-generation lipid nanoparticle (LNP) technology. The acquisition involves investing funds equivalent to the value of the patents and providing two to three years' worth of research and development funding. Luna RD holds patents for novel components crucial to LNP technology and possesses unique methods to develop LNPs without polyethylene glycol (PEG). This innovative approach offers new delivery options in the nucleic acid drug field, addressing existing limitations such as tissue constraints and antibody production against PEG lipids. By acquiring Luna RD, Nano Holdings seeks to enhance NANO MRNA’s competitive edge and expand opportunities for joint ventures and licensing agreements with pharmaceutical companies and biotech firms.
The acquired company, Luna RD, was established in November 2021 with a capital of ¥1 million. As of October 31, 2025, Luna RD reported total assets of ¥118,197 and net assets of ¥118,197. The company also recorded operating losses of ¥2.82 million and a lower net profit of ¥218,474 for the fiscal year ending October 31, 2025. The transaction will involve issuing ordinary shares totaling 200,040 to Luna RD, increasing Nano Holdings’ stake to 66.67%. The payment period for the capital increase runs from May 18 to May 29, 2026, with the final payment due on May 29, 2026.
The deal is expected to result in goodwill but the impact on the consolidated performance for the fiscal year ending March 2027 is currently being assessed.
🟡 Confidence: Standard AI-translated content.